anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
Immix Biopharma · pitchdeck

Immix Biopharma | Investor Presentation Deck | 57 slides

57 pages · 8 arc beats · 4 loops

Pitchdeck Download JSON
Unlock

Immix Biopharma | Investor Presentation Deck | 57 slides

Immix Biopharma · 2023-10
arc beats above · slides in the middle · loops below · scroll → 4 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

8
coverage by narrative range · generated from this deck JSON
Narrative range 57 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Hook 3 slides 100% 3/3 slides 100% 3/3 slides · 11 hits
— 0/3 slides
33.3% 1/3 slides 33.3% 1/3 slides 100% 3/3 slides
— 0/3 slides
Problem (Identify pain) 2 slides 100% 2/2 slides 100% 2/2 slides · 10 hits
— 0/2 slides
50% 1/2 slides 100% 2/2 slides 100% 2/2 slides 100% 2/2 slides Situation & Context 5 slides 100% 5/5 slides 100% 5/5 slides · 26 hits
— 0/5 slides
60% 3/5 slides · 4 hits 40% 2/5 slides 100% 5/5 slides 100% 5/5 slides Evidence & Proof 6 slides 100% 6/6 slides 100% 6/6 slides · 27 hits
— 0/6 slides
33.3% 2/6 slides 66.7% 4/6 slides 100% 6/6 slides 100% 6/6 slides Visualization 6 slides 100% 6/6 slides 100% 6/6 slides · 33 hits
— 0/6 slides
— 0/6 slides
66.7% 4/6 slides 100% 6/6 slides 100% 6/6 slides Desire 6 slides 100% 6/6 slides 100% 6/6 slides · 23 hits
— 0/6 slides
33.3% 2/6 slides 66.7% 4/6 slides 100% 6/6 slides
— 0/6 slides
Interest 8 slides 100% 8/8 slides 100% 8/8 slides · 42 hits
— 0/8 slides
— 0/8 slides
50% 4/8 slides 100% 8/8 slides
— 0/8 slides
Satisfaction 21 slides 100% 21/21 slides 100% 21/21 slides · 106 hits
— 0/21 slides
42.9% 9/21 slides 23.8% 5/21 slides 100% 21/21 slides
— 0/21 slides

Slide inventory

57
every slide · same image gating as the playbook
01
Slide 1
Includes date and ticker symbol.front_matter
Open slide detailBeat · Hook
02
other
Open slide detailBeat · Hook
03
The slide uses a numbered list format to present key value propositions.summarize
Open slide detailBeat · Hook
04
Uses a hub-and-spoke diagram to illustrate the central problem of CAR-T neurotoxicity and its four primary negative impacts.frame_problem
Open slide detailBeat · Problem (Identify pain)Loop · Cost Of Inaction
05
Includes a cartoon mascot at the bottom.present_solution
Open slide detailBeat · Problem (Identify pain)Loop · Cost Of Inaction
06
The slide uses a bar chart combined with a data table to highlight safety advantages. It includes a disclaimer about cross-trial comparisons.compare_peers
Open slide detailBeat · Situation & ContextLoop · Golden Circle
07
Uses icon-based visualization to represent market expansion from 5% of hospitals to a much broader network.size_opportunity
Open slide detailBeat · Situation & ContextLoop · Golden Circle
08
The slide highlights the structural difference of the NXC-201 molecule compared to Abecma, Carvykti, and CART-ddBCMA.present_solution
Open slide detailBeat · Situation & ContextLoop · Golden Circle
09
Includes comparative bar charts and flow cytometry data.present_solution
Open slide detailBeat · Situation & ContextLoop · Golden Circle
10
The slide uses a comparative timeline visualization to highlight the superior safety and efficacy profile of NXC-201.compare_peers
Open slide detailBeat · Situation & ContextLoop · Golden Circle
11
The chart illustrates the mechanism of action and efficacy of NXC-201 (formerly HBI0101) in treating AL Amyloidosis.show_traction
Open slide detailBeat · Evidence & ProofLoop · Hypothesis Test
12
The slide uses a process flow diagram to illustrate the disease mechanism and a human anatomy diagram to show clinical manifestations.frame_problem
Open slide detailBeat · Evidence & ProofLoop · Hypothesis Test
13
The slide uses a dual-metric comparison (Hematologic Response vs. Cardiac Response) to highlight NXC-201's efficacy.compare_peers
Open slide detailBeat · Evidence & ProofLoop · Hypothesis Test
14
The slide uses a table structure to contrast treatment efficacy and patient outcomes, with a bar chart at the bottom illustrating patient population growth.compare_peers
Open slide detailBeat · Evidence & ProofLoop · Hypothesis Test
15
The slide uses a visual comparison to highlight a 67% improvement in response rates for NXC-201 compared to competitors.compare_peers
Open slide detailBeat · Evidence & ProofLoop · Hypothesis Test
16
Includes a footer citing FDA approval precedents for similar single-arm studies.plan_implementation
Open slide detailBeat · Evidence & ProofLoop · Hypothesis Test
17
Includes detailed clinical trial references in the footer.compare_peers
Open slide detailBeat · VisualizationLoop · Why Now
18
The slide uses a two-column layout to track progress for two distinct drug programs.plan_implementation
Open slide detailBeat · VisualizationLoop · Why Now
19
The slide uses a side-by-side comparison structure to explain two distinct but complementary technology platforms.present_solution
Open slide detailBeat · VisualizationLoop · Why Now
20
The slide uses a standard pharmaceutical pipeline table format.plan_implementation
Open slide detailBeat · VisualizationLoop · Why Now
21
Includes a comparative table of clinical outcomes (ORR/CR/sCR) for NXC-201 vs competitors.size_opportunity
Open slide detailBeat · VisualizationLoop · Why Now
22
The slide uses a wave-like visual to represent market size, with specific dollar amounts associated with different disease categories.size_opportunity
Open slide detailBeat · VisualizationLoop · Why Now
23
transition
Open slide detailBeat · Desire
24
The slide uses a red dashed box to highlight the primary efficacy metrics for comparison.compare_peers
Open slide detailBeat · Desire
25
The chart uses a grouped bar structure to compare NXC-201 (green) against other therapies (blue/red/grey).compare_peers
Open slide detailBeat · Desire
26
The slide uses a red dashed box to highlight the key clinical data rows (ORR, CR, ICANS, CRS).compare_peers
Open slide detailBeat · Desire
27
The slide uses a side-by-side comparison of two disease indications, showing clinical results, relevant competitor benchmarks, and market size.show_traction
Open slide detailBeat · Desire
28
The chart demonstrates deepening clinical responses over time for NXC-201 therapy.show_traction
Open slide detailBeat · Desire
29
The table displays clinical trial data for NXC-201, specifically focusing on safety profiles and management interventions.analyze_data
Open slide detailBeat · Interest
30
The slide highlights specific safety metrics (CRS and ICANS) for two dosage groups (100x10^6 and 300x10^6 cells).compare_peers
Open slide detailBeat · Interest
31
The slide uses a step-wise process diagram to illustrate dose escalation.plan_implementation
Open slide detailBeat · Interest
32
The slide features a scientific illustration of cellular structures, likely representing the drug's mechanism of action or target environment.transition
Open slide detailBeat · Interest
33
Includes scientific diagrams of molecular pathways and efficacy data charts.present_solution
Open slide detailBeat · Interest
34
Slide contains three distinct charts comparing IMX-110 against standard of care and other combinations in mouse models.analyze_data
Open slide detailBeat · Interest
35
Includes a process diagram illustrating the mechanism of action of IMX-110 in turning cold tumors hot.show_traction
Open slide detailBeat · Interest
36
Includes Kaplan-Meier survival curves and bioluminescence imaging of tumor activity.show_traction
Open slide detailBeat · Interest
37
transition
Open slide detailBeat · Satisfaction
38
Includes waterfall charts and longitudinal patient response plots. Source note provided at bottom.show_traction
Open slide detailBeat · Satisfaction
39
The slide uses a bubble chart to map clinical trials and a table to summarize drug performance metrics, highlighting low efficacy and high toxicity.frame_problem
Open slide detailBeat · Satisfaction
40
The slide uses a combination of a conceptual chart and a data table to highlight efficacy and safety in a small sample size (n=4).show_traction
Open slide detailBeat · Satisfaction
41
The slide uses a process flow diagram to show trial progression for two distinct treatment arms.plan_implementation
Open slide detailBeat · Satisfaction
42
transition
Open slide detailBeat · Satisfaction
43
The slide uses a process-flow layout to connect platform capabilities to specific product outputs.present_solution
Open slide detailBeat · Satisfaction
44
The slide uses a '3 Pillars' framework to explain the platform foundation, followed by a product-specific breakdown.present_solution
Open slide detailBeat · Satisfaction
45
Includes technical diagrams of the drug delivery mechanism and comparative survival data.present_solution
Open slide detailBeat · Satisfaction
46
Includes two sets of charts: tumor volume over time and survival curves. References specific dosing schedules and study parameters.show_traction
Open slide detailBeat · Satisfaction
47
Includes detailed scientific diagrams of the drug mechanism and clinical trial results.present_solution
Open slide detailBeat · Satisfaction
48
transition
Open slide detailBeat · Satisfaction
49
The slide is divided into two sections: ImmixBio Clinical Advisory Board (top) and Select Nexcella Scientific Advisory Board (bottom).other
Open slide detailBeat · Satisfaction
50
other
Open slide detailBeat · Satisfaction
51
The slide is organized into two rows, one for each company's board members, featuring headshots, names, titles, and company logos.other
Open slide detailBeat · Satisfaction
52
The slide uses a numbered list format to present key value propositions.summarize
Open slide detailBeat · Satisfaction
53
appendix
Open slide detailBeat · Satisfaction
54
Highlights NXC-201's lower fludarabine dose and Carvykti's longer infusion window.compare_peers
Open slide detailBeat · Satisfaction
55
The slide uses a combination of expert testimonials and a comparative clinical trial table to validate the outpatient administration model.show_traction
Open slide detailBeat · Satisfaction
56
The slide uses a bar chart to contrast the combined annual sales of two sets of oncology drugs.size_opportunity
Open slide detailBeat · Satisfaction
57
The slide compares efficacy benchmarks of established competitors (AbbVie, J&J, Takeda) to set a baseline for the IMX-120 opportunity.compare_peers
Open slide detailBeat · Satisfaction